MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasd ...

Cytokinetics, Incorporated (NASDAQ:CYTK) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the fifteen best healthcare stocks on our list. TheFly reported on February 3 that Truist raised its price target on CYTK to $92 from $84 and maintained a Buy rating. The company revised its model ahead of its Q4 results to account for t ...